Lausanne, Switzerland – October 15, 2014 – Spinomix SA a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector, today announced the issuance of two US Patents number US 8,585,279 and US 8,870,446 relating to the manipulation and mixing of magnetic particles in microfluidics environments.

Spinomix Granted New US Patents for its MagPhase Core Technology

 

  • Automated sample preparation platform based on magnetic beads and microfluidics
  • Robust and highly flexible automation brought to every laboratory bench
  • Offers new avenues in assay processing for life science research and diagnostics
  • Company in discussions with commercial partners and in process of raising new funds

 

Lausanne, Switzerland – October 15, 2014 – Spinomix SA a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector, today announced the issuance of two US Patents number US 8,585,279  and US 8,870,446 relating to the manipulation and mixing of magnetic particles in microfluidics  environments.


Spinomix's proprietary technology MagPhase™ has also been granted protection in China and Japan and is in its final granting stages in Europe. These highly strategic patents raise the company's MagPhase™ US granted patent portfolio to three patents; three others are still pending approval.


“This new patent grant is of great strategic importance for Spinomix since it confirms the originality of our method and its capability of leveraging the great applications possible with magnetic beads based assays and their easy automation using microfluidic based systems,” said Amar Rida, Founder and Chief Technology Officer of Spinomix. “Our company is continuously committed to innovation in order to provide the marketplace with novel solutions capable of shortening the path between sample collection and results analysis.”


Although magnetic beads technology has been around since the mid 1970s, the uniqueness of the company’s MagPhase™ technology is in the innovative way of homogenously handling these beads in connection with fluids handling in microfluidics based systems, thus enhancing bioassays efficiency and opening new  fields for sample processing automation. The company’s goal with MagPhase™ is to bring affordable and flexible automation to every laboratory bench.

The technology is being developed for life science research as well as applications which are critical for treatment decisions such as circulation tumour nucleic acids for cancer diagnosis or cell isolation in regenerative medicine.


“Our vision is to expand our microfluidics cartridges to all of the currently available applications of magnetic beads such as protein purification, cell isolation and others. We are already applying our technology to nucleic acid purification, a market estimated to be well over one billion dollars,” said Spinomix Chief Executive Officer Nasri Nahas. “Spinomix is well on its way to becoming a sustainable business, supported by discussions with major market players to bring our products to market.”


Full details on the attached press release

www.spinomix.com
 

Find an actor

BioAlps World Visibitlity Package 201918.03.2019

A yearly international programme for our affiliated companies to increase their visibility.

Stolmár & Partner Intellectual Property S.à.r.l.Professional Services & Consulting, Patent & Trademarks

Stolmár & Partner is a steadily growing IP law firm with a strong focus on life sciences (Biotech, pharma, diagnostics), medtech and software protection. S & P counts at present 14 patent, trademark and design attorneys. Our attorneys are admitted to practice before the European Patent Office (EPO), the Swiss Patent and Trademark Office (IGE), the German Patent and Trademark Office (GPTO), EUIPO, WIPO, Switzerland’s and Germany’s Federal Patent Court and the German Federal Supreme Court. Some of our attorneys are also admitted before the, Italian, French and the Austrian Patent and Trademark offices thus offering a seamless truly pan-european one-stop service for our clients. Besides our Geneva office, the headquarter is in Munich in close proximity to the EPO. We have further branch offices in the Lake Constance region (Neuhausen ob Eck) and in Hamburg. Our attorneys and agents are carefully recruited for their technical expertise and industrial experience. Most have earned an advanced technical degree and have significant industrial or academic experience across a wide spectrum of technical areas. While the firm provides a full range of services, it is organized internally around four main practice groups. They are the Chemical/Life Sciences Group, the Electrical/Software, the Medtech/Mechanical Group and the Trademark/Design group. Further S & P advises ist clients in Arbitration, Regulatory affairs and License agreements as well as in IP Due Diligence and expert opinions. Our IP lawyers are trained to evaluate intellectual property in the context of client business issues to ensure alignment with company goals. Strong patent claims constructed around strategic goals are invaluable as our clients commercialize ideas and defend leadership positions via litigation and oppositions. A special focus of the firm is opposition proceedings before the EPO and invalidation proceedings before the German Federal Patent Court. Practicing in Munich and at various european hightech spots is a distinct advantage. The firm’s proximity to the European Patent Office (EPO), the Federal Patent Court and the district court for litigation, allows us the opportunity to help shape the IP landscape. Attorneys can easily conduct in-person interviews at the EPO and form substantive professional relationships with examiners given our regular presence at the EPO.
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn